Barriers to Medical Provider Support for Prescription Naloxone As Overdose Antidote for Lay Responders

REFERENCES

• Albert, S., Brason Ii, F. W., Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in Rural North Carolina. Pain Medicine, 12, S77–S85.
   PubMed Web of Science ®Google Scholar
• American Medical Association. (2012). AMA adopts new policies at annual meeting. Retrieved September, 28, 2012, from http://www.ama-assn.org/ama/pub/news/news/2012–06–19-ama-adopts-new-policies.page
   Google Scholar
• Barreras, R. E., Drucker, E. M., & Rosenthal, D. (2005). The concentration of substance use, criminal justice involvement, and HIV/AIDS in the families of drug offenders. Journal of Urban Health, 82(1), 162–170.
   PubMed Web of Science ®Google Scholar
• Beletsky, L., Bell, A., Bowman, S., Burris, S., Dasgupta, N., Doe-Simkins, M., (2012). Retrieved September 19, 2012, from www.prescribetoprevent.org
   Google Scholar
• Beletsky, L., Ruthazer, R., Macalino, G. E., Rich, J. D., Tan, L., & Burris, S. (2007). Physicians’ knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: Challenges and opportunities. Journal of Urban Health, 84(1), 126–136.
   PubMed Web of Science ®Google Scholar
• Boyer, E. W. (2012). Management of opioid analgesic overdose. The New England Journal of Medicine, 367(2), 146–155.
   PubMed Web of Science ®Google Scholar
• Campbell, R. L., Luke, A., Weaver, A. L., St Sauver, J. L., Bergstralh, E. J., Li, J. T., (2008). Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis. Annals of Allergy, Asthma & Immunology, 101(6), 631–636.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). (2012). CDC grand rounds: Prescription drug overdoses—a U.S. epidemic. MMWR Morbidity and Mortality Weekly Report, 61(1), 10–13.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2010). QuickStats: Death rates for the three leading causes of injury death — United States, 1979–2007. MMWR Morbidity and Mortality Weekly Report, 59(30), 957.
   Google Scholar
• Centers for Disease Control and Prevention. (2012b). Community-based opioid overdose prevention programs providing naloxone — United States, 2010. MMWR Morbidity and Mortality Weekly Report, 61(6), 101–105.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. (2012c). Vital Signs, Injury: The #3 killer of Children U.S. Retrieved October 15, 2012, from http://www.cdc.gov/vitalsigns/ChildInjury/ infographic.html?s_cid=bb-vitalsigns-124
   Google Scholar
• Chelminski, P. R., Ives, T. J., Felix, K. M., Prakken, S. D., Miller, T. M., Perhac, J. S., (2005). A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Research Journal, 5(1), 3.
   PubMedGoogle Scholar
• Clark, S., Bock, S. A., Gaeta, T. J., Brenner, B. E., Cydulka, R. K., & Camargo, C. A. (2004). Multicenter study of emergency department visits for food allergies. Journal of Allergy and Clinical Immunology, 113(2), 347–352.
   Google Scholar
• Clark, S., Long, A. A., Gaeta, T. J., & Camargo, C. A., Jr. (2005). Multicenter study of emergency department visits for insect sting allergies. Journal of Allergy and Clinical Immunology, 116(3), 643–649.
   Google Scholar
• Coffin, P. O., Fuller, C., Vadnai, L., Blaney, S., Galea, S., & Vlahov, D. (2003). Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. Journal of Urban Health, 80(2), 288–290.
   PubMed Web of Science ®Google Scholar
• Dasgupta, N., Sanford, C., Albert, S., & Wells Brason, F. (2010). Opioid drug overdoses: A prescription for harm and potential for prevention. American Journal of Lifestyle Medicine, 4(1), 32–37.
   Google Scholar
• Davis, C., & Chang, S. (2012). Legal interventions to reduce overdose mortality: Naloxone access and overdose Good Samaritan Laws. Retrieved October 15, 2012, from http:// www.networkforphl.org/_asset/qz5pvn/naloxone-_FINAL.pdf
   Google Scholar
• Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009). Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health, 99(5), 788–791.
   PubMed Web of Science ®Google Scholar
• Fenichel, R. R. (2004). Which drugs should be available over the counter? British Medical Journal, 329(7459), 182–183.
   Google Scholar
• Gupta, R. S., Springston, E. E., Kim, J. S., Smith, B., Pongracic, J. A., Wang, X., (2010). Food allergy knowledge, attitudes, and beliefs of primary care physicians. Pediatrics, 125(1), 126–132.
   PubMed Web of Science ®Google Scholar
• Heimer, R., Dasgupta, N., Irwin, K. S., Kinzly, M., Harvey, A. P., Givens, A., (2012). Chronic pain, addiction severity, and misuse of opioids in Cumberland County, Maine. Addictive Behaviors, 37(3), 346–349.
   Google Scholar
• Hurley, R. (2011). Pilot scheme shows that giving naloxone to families of drug users would save lives. British Medical Journal, 343. BMJ 2011;343:d5445. Retrieved November 1, 2011 from http://dx.doi.org/10.1136/bmj.d5445.
   Google Scholar
• Kahan, M., Srivastava, A., Wilson, L., Gourlay, D., & Midmer, D. (2006). Misuse of and dependence on opioids: Study of chronic pain patients. Canadian Family Physician, 52(9), 1081–1087.
   PubMedGoogle Scholar
• Kidorf, M., & King, V. L. (2008). Expanding the public health benefits of syringe exchange programs. Canadian Journal of Psychiatry, 53(8), 487–495.
   PubMed Web of Science ®Google Scholar
• Manchikanti, L., Abdi, S., Atluri, S., Balog, C. C., Benyamin, R. M., Boswell, M. V., (2012). American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2—guidance. Pain Physician, 15(3 Suppl), S67–S116.
   PubMed Web of Science ®Google Scholar
• Maxwell, S., Bigg, D., Stanczykiewicz, K., & Carlberg-Racich, S. (2006). Prescribing naloxone to actively injecting heroin users. Journal of Addictive Diseases, 25(3), 89–96.
   PubMed Web of Science ®Google Scholar
• Mayet, S., Manning, V., Williams, A., Loaring, J., & Strang, J. (2011). Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: Effective, but dissemination is challenging. International Journal of Drug Policy, 22(1), 9–15.
   Google Scholar
• Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007). Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. The Annals of Family Medicine, 5(2), 146–150.
   PubMed Web of Science ®Google Scholar
• Miotto, K., Hillhouse, M., Donovick, R., Cunningham-Rathner, J., Charuvastra, C., Torrington, M., (2012). Comparison of buprenorphine treatment for opioid dependence in 3 settings. Journal of Addiction Medicine, 6(1), 68–76.
   Google Scholar
• Paulozzi, L. J., Budnitz, D. S., & Xi, Y. (2006). Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Safety, 15(9), 618–627.
   PubMed Web of Science ®Google Scholar
• Peles, E., Schreiber, S., Gordon, J., & Adelson, M. (2005). Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain, 113(3), 340–346.
   PubMed Web of Science ®Google Scholar
• Potter, J. S., Shiffman, S. J., & Weiss, R. D. (2008). Chronic pain severity in opioid-dependent patients. American Journal of Drug and Alcohol Abuse, 34(1), 101–107.
   PubMed Web of Science ®Google Scholar
• Raisch, D. W., Fye, C. L., Boardman, K. D., & Sather, M. R. (2002). Opioid dependence treatment, including buprenorphine/naloxone. Annals of Pharmacotherapy, 36(2), 312–321.
   PubMed Web of Science ®Google Scholar
• Rosenblum, A., Joseph, H., Fong, C., Kipnis, S., Cleland, C., & Portenoy, R. K. (2003). Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. Journal of the American Medical Association, 289(18), 2370–2378.
   PubMed Web of Science ®Google Scholar
• Sampson, H. A., Munoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Jr., Bock, S. A., Branum, A., (2006). Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Journal of Allergy and Clinical Immunology, 117(2), 391–397.
   Google Scholar
• Savage, S. R., Kirsh, K. L., & Passik, S. D. (2008). Challenges in using opioids to treat pain in persons with substance use disorders. Addiction Science & Clinical Practice, 4(2), 4–25.
   PubMedGoogle Scholar
• Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012). Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Journal of General Internal Medicine, 27(6), 669–676.
   PubMed Web of Science ®Google Scholar
• Sentencing. 4th circuit: HIV diagnosis not valid excuse to violate probation. (2009). AIDS Policy Law, 24(2), 6.
   Google Scholar
• Sheu, R., Lussier, D., Rosenblum, A., Fong, C., Portenoy, J., Joseph, H., (2008). Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Medicine, 9(7), 911–917.
   Google Scholar
• Stimson, G. V., Donoghoe, M., Fitch, C., Rhodes, T. J., Ball, A., & Weiler, G. (2003). Rapid assessment and response technical guide. World Health Organization (Department of Child and Adolescent Health and Development, and Department of HIV/AIDS). Geneva, Switzerland.
   Google Scholar
• Walley, A. (2011, November). Implementation and evaluation of Massachusetts’ overdose education and naloxone distribution program. Paper presented at the APHA 139th Annual Meeting and Exposition, Washington DC.
   Google Scholar
• Warner, M., Chen, L. H., & Makuc, D. M. (2009). Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS Data Brief (22), 1–8. Hyattsville, MD: National Center for Health Statistics, 2009.
   PubMedGoogle Scholar
• Yawn, B. P., & Fenton, M. J. (2012). Summary of the NIAID-sponsored food allergy guidelines. American Family Physician, 86(1), 43–50.
   Google Scholar
• Yu, J. E., Kumar, A., Bruhn, C., Teuber, S. S., & Sicherer, S. H. (2008). Development of a food allergy education resource for primary care physicians. BMC Medical Education, 8, 45.
   Google Scholar
• Zaller, N., Jeronimo, A., Bratberg, J., Case, P., & Rich, J. D. (2010). Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. Journal of Urban Health, 87(6), 942–953.
   PubMed Web of Science ®Google Scholar
• Zaller, N. D., Yokell, M. A., Green, T. C., Gaggin, J. W., & Case, P. (in press). The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse.
   Google Scholar